Nanotechnology Now - Press Release: Arrowhead to Report Fiscal 2012 Second Quarter Financial Results: Conference call Scheduled for Tuesday, May 8, 2012

Home > Press > Arrowhead to Report Fiscal 2012 Second Quarter Financial Results: Conference call Scheduled for Tuesday, May 8, 2012

Abstract:
Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2012 second quarter ended March 31, 2012, on Tuesday, May 8, 2012 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the conference call, please dial 1-877-317-6789 (toll free from the US and Canada), or 1-412-317-6789 (for international callers). Investors may also access a live audio webcast of this conference call on the Company's website at www.arrowheadresearch.com.

Arrowhead to Report Fiscal 2012 Second Quarter Financial Results: Conference call Scheduled for Tuesday, May 8, 2012

Pasadena, CA | Posted on May 1st, 2012

A replay of the webcast will be available approximately two hours after the conclusion of the call. The webcast archive will remain available until 2/9/2013. An audio replay will also be available approximately one hour after the conclusion of the call and will be made available until Wednesday, May 16, 2012. The audio replay can be accessed by dialing 1-877-344-7529 (toll free from the US and Canada), or 1-412-317-0088 (for international callers) and entering Event ID 10013625.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage nanomedicine company developing innovative therapies at the interface of biology and nanoengineering. Arrowhead's world-class capabilities and intellectual property covering nucleic acid delivery, siRNA chemistry, and tissue targeting allow it to design and develop therapeutic agents for a wide range of diseases. The company's lead products include CALAA-01, an oncology drug candidate based on the gene silencing RNA interference (RNAi) mechanism, and AdipotideTM, an anti-obesity peptide that targets and kills the blood vessels that feed white adipose tissue. Arrowhead is leveraging its proprietary Dynamic PolyConjugateTM (DPC), Liposomal Nanoparticle (LNP), and RONDELTM delivery platforms to support its own pipeline of preclinical and clinical candidates and to secure external partnerships and collaborations with biotech and pharmaceutical companies.

For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to

For more information, please click here

Contacts:
Investor Relations Contact:
Michael Levitan
The Trout Group, LLC
646-378-2920

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: